🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "major milestone" in the fight against increasingly resistant strains of the pathogen, according to researchers.

A Global Health Concern

Gonorrhoea infections are escalating around the world, with estimates suggesting over 82 million instances each year. Especially elevated rates are reported in Africa and nations within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. Within England, cases have hit a record high, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune advancement in the context of increasing worldwide cases, increasing antimicrobial resistance and the very limited therapeutic options currently available.”

Medical experts are particularly alarmed about the surge in treatment-resistant strains. The WHO has listed it as a "high-priority threat". A tracking program revealed that the effectiveness of primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Treatment Options Receive Authorization

Zoliflodacin, also known as Nuzolvence, was authorized by the US FDA in mid-December for use against gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Researchers hope that targeted use of this new drug will help slow the development of resistance.

Gepotidacin, originating from the drugmaker GSK, gained clearance in the same week. This medication, which is employed against UTIs, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin stemmed from a unique collaborative effort for drug creation. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to develop it.

“This authorization marks a major breakthrough in the management of multidrug-resistant gonorrhoea, which until now has been staying ahead of antibiotic development.”

Clinical Trial Results and Global Access

Based on findings released by a prominent scientific publication, zoliflodacin cured the vast majority of uncomplicated infections. This establishes an similar efficacy with the current standard treatment, which combines two antibiotics. The research involved nearly 1,000 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, GARDP has the rights to make available and distribute the drug in many regions with limited resources.

Doctors on the front lines have expressed optimism. Having a single-dose, oral treatment like this is seen as a "game-changer" for managing the epidemic. This is viewed as crucial to alleviate the strain of the infection for patients and to prevent the spread of extremely resistant gonorrhoea globally.